摘要:As it is known, more and more genes' single nucleotide polymorphisms (SNPs) were associated with some diseases, the pharmacokinetics and the targets of drug effects. Detecting specific genotypes could be helpful to choose specific regimen in different individuals, which could result in a better treatment effects and reduced adverse events. In addition, the abnormal chromosomes and fusion genes were common in hematological malignances. To detecting these associated genes could contribute to the precise selection of specific targeted therapy and the better understanding of the prognosis.
[1] Duan XH, Zhou HH. Induction mechanism and research progress of CYP2C9. Chin Pharmacol Bull, 2004,20(9):961-965.
[2] Taube J, Halsall D, Baqlin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96(5):1816-1819.
[3] Margaglione M, Colaizzo D, D’Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost, 2000,84(5):775-778.
[4] Miners JO, Coulter S, Birkett DJ, et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics, 2000,10(3):267-270.
[5] Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol, 1996,49(2):311-318.
[6] Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA, 1998,95(22):13176-13181.
[7] Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001,27(4):383-391.
[8] Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001,70(2):189-199.
[9] Dai S, Mao C, Jiang L, et al. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies. Human Genetics, 2009,125(5-6):633-638.
[10] Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet, 2008,47(9):565-594.
[11] Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med, 2008,358(10):999-1008.
[12] Zhu Y, Shennan M, Reynolds K K, et al. Estimation of warfarin maintenance dose based on VKORC1(-1639 G>A)and CYP2C9 genotypes. Clin Chem, 2007,53(7):1721-1722.
[13] Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med,2005,352(22):2285-2293.
[14] Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL). Cancer, 2007,109(10):2068-2076.
[15] Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia, 2002,16(9):1579-1583.
[16] Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood, 2006,107(10):4039-4046.
